Investment Summary

HBM Partners AG Invests In NiKang Therapeutics

On September 14, 2020, private equity firm HBM Partners AG invested in life science company NiKang Therapeutics

Investment Highlights
  • This is HBM Partners AG’s 34th transaction in the Life Science sector.
  • This is HBM Partners AG’s 27th transaction in the United States.
  • This is HBM Partners AG’s 1st transaction in Delaware.

Investment Summary
Date 2020-09-14
Target NiKang Therapeutics
Sector Life Science
Investor(s) HBM Partners AG
Deal Type Venture

Target

NiKang Therapeutics

Wilmington, Delaware, United States
NiKang Therapeutics is a clinical stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. NiKang’s discovery approach is informed by target structure biology and capitalizes on structure-based drug design enabling a rapid and efficient discovery and development of proprietary drug candidates with the most desirable pharmacological features into clinical studies. NiKang Therapeutics was founded in 2017 and is based in Wilmington, Delaware.

Search 202,137 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

HBM Partners AG

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 2001
PE ASSETS 3.0B USD
Size Mega
Type Sector Focused
DESCRIPTION

HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.

DEAL STATS #
Overall 41 of 66
Sector (Life Science) 34 of 57
Type (Venture) 32 of 53
State (Delaware) 1 of 1
Country (United States) 27 of 44
Year (2020) 10 of 17
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-08-24 Connect Biopharma

San Diego, California, United States

Connect Biopharma is a global biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. Connect Biopharma was founded in 2012 and is based in San Diego, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-09-16 Polyneuron

Basel, Switzerland

Polyneuron has a unique approach in using antigen-specific polymers to target and eliminate the pathological antibodies causing serious autoimmune diseases with a high unmet medical need. Polyneuron was founded in 2014 and is based in Basel, Switzerland.

Buy -
Mergr

Product

Company

Legal